SCHEMBL16655314

SCHEMBL16655314

C=CCOc1cc(O)cc(-c2nn(C3Cc4ccccc4C3)c3ncnc(N)c23)c1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 16/20 0.69
BTK Q06187 13/20 0.69
ATR Q13535 4/20 0.59
PIK3CA P42336 2/20 0.51
PIK3CB P42338 2/20 0.51
PIK3CG P48736 2/20 0.51
PRKDC P78527 2/20 0.51
ABL1 P00519 1/20 0.51
EGFR P00533 1/20 0.51
HCK P08631 1/20 0.51
SRC P12931 1/20 0.51
KDR P35968 1/20 0.51
MTOR P42345 1/20 0.51
EPHB4 P54760 1/20 0.51
PI4KB Q9UBF8 1/20 0.51
FGFR1 P11362 1/20 0.48
FGFR2 P21802 1/20 0.48
FGFR4 P22455 1/20 0.48
FGFR3 P22607 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16655631 0.94 PIK3CD (0.72) PIK3CDBTKATR
SCHEMBL16655178 0.88 BTK (0.61) PIK3CDBTKATRABL1EGFR
SCHEMBL16655690 0.88 BTK (0.55) PIK3CDBTKABL1EGFRHCK
SCHEMBL16656017 0.86 PIK3CD (0.69) PIK3CDBTKATRPIK3CAPIK3CB
SCHEMBL16655653 0.85 PIK3CD (0.76) PIK3CDBTKATRPIK3CAPIK3CB
SCHEMBL16655342 0.85 PIK3CD (0.73) PIK3CDBTKATRPIK3CAPIK3CB
SCHEMBL16655956 0.84 PIK3CD (0.79) PIK3CDBTKATR
SCHEMBL16655962 0.82 ATR (0.67) PIK3CDBTKATRPIK3CAPIK3CB
SCHEMBL16655498 0.82 PIK3CD (1.00) PIK3CDBTKATRPIK3CAPIK3CB
SCHEMBL16655166 0.82 PIK3CD (1.00) PIK3CDBTKATRPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317140-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2021-10-14 US claimed
EP-3057970-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Medivation Technologies, Inc. (US) 2016-08-24 EP claimed
WO-2015058084-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2015-04-23 WO claimed
US-20210317140-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2021-10-14 US disclosed
WO-2015058084-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2015-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317140-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB PIK3CD 2/4885BTK 1/4885ATR 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.